These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37387486)

  • 1. Clot Waveform Analysis for Hemostatic Abnormalities.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Shimaoka M
    Ann Lab Med; 2023 Nov; 43(6):531-538. PubMed ID: 37387486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis.
    Fukui S; Wada H; Ikeda K; Kobayashi M; Shimada Y; Nakazawa Y; Mizutani H; Ichikawa Y; Nishiura Y; Moritani I; Yamanaka Y; Inoue H; Shimaoka M; Shimpo H; Shiraki K
    Clin Appl Thromb Hemost; 2024; 30():10760296241246002. PubMed ID: 38591954
    [No Abstract]   [Full Text] [Related]  

  • 3. A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms.
    Kobayashi M; Wada H; Fukui S; Mizutani H; Ichikawa Y; Shiraki K; Moritani I; Inoue H; Shimaoka M; Shimpo H
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.
    Wada H; Ichikawa Y; Ezaki M; Shiraki K; Moritani I; Yamashita Y; Matsumoto T; Masuya M; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
    Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Factor VIII Concentrates Using Clot Waveform Analysis.
    Wada H; Shiraki K; Matsumoto T; Shimpo H; Sakano Y; Nishii H; Tamaki S; Suzuki K; Tawara I; Yamashita Y; Shimaoka M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999423
    [No Abstract]   [Full Text] [Related]  

  • 7. The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients.
    Hasegawa M; Tone S; Wada H; Naito Y; Matsumoto T; Yamashita Y; Shimaoka M; Sudo A
    Clin Appl Thromb Hemost; 2021; 27():10760296211012094. PubMed ID: 34027710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Detection of Hypercoagulability in Patients with Acute Cerebral Infarction Using a Clot Waveform Analysis.
    Kamon T; Horie S; Inaba T; Ito N; Shiraki K; Ichikawa Y; Ezaki M; Shimpo H; Shimaoka M; Nishigaki A; Shindo A; Wada H
    Clin Appl Thromb Hemost; 2023; 29():10760296231161591. PubMed ID: 36872898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
    Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clot Waveform Analysis for Monitoring Hemostasis.
    Nogami K
    Semin Thromb Hemost; 2023 Sep; 49(6):592-599. PubMed ID: 36174610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
    Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
    Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Shimaoka M
    Thromb Res; 2020 Sep; 193():146-153. PubMed ID: 32559572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Reevaluation of Thrombin Time Using a Clot Waveform Analysis.
    Wada H; Ichikawa Y; Ezaki M; Matsumoto T; Yamashita Y; Shiraki K; Shimaoka M; Shimpo H
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis.
    Maeda K; Wada H; Shinkai T; Tanemura A; Matsumoto T; Mizuno S
    Thromb Res; 2021 May; 201():154-160. PubMed ID: 33862519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance and Interpretation of Clot Waveform Analysis.
    Ruberto MF; Marongiu F; Barcellona D
    Methods Mol Biol; 2023; 2663():163-173. PubMed ID: 37204709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation Status Using Clot Wave Analysis in Patients With Prolonged Immobilization.
    Iberahim S; Muhamat Yusoff R; Mohd Noor NH; Hassan R; Ramli NN; Bahar R; Zulkafli Z; Wan Ab Rahman WS; Ab Ghani AS
    Cureus; 2024 Jan; 16(1):e51483. PubMed ID: 38304638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis.
    Haku J; Nogami K; Matsumoto T; Ogiwara K; Shima M
    J Thromb Haemost; 2014; 12(3):355-62. PubMed ID: 24354697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay.
    Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Sakano Y; Nishii H; Shimaoka M
    Clin Appl Thromb Hemost; 2021; 27():1076029620976913. PubMed ID: 33606948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.
    Kato K; Hatayama Y; Shimohiro H; Ichikawa H; Fukuda T
    Yonago Acta Med; 2022 Aug; 65(3):226-230. PubMed ID: 36061578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.